Huge Samsung BioLogics IPO Reflects Rosy Manufacturing Outlook
Executive Summary
Samsung BioLogics has successful floated in one of South Korea’s largest ever IPOs and appears to be on track to becoming the top global contract manufacturer of biologics amid rising demand from cost-conscious global clients.
You may also be interested in...
Samsung BioLogics Under Spotlight Over Accounting Handling Of Biogen JV
Samsung BioLogics shares plunge on suspicions it has violated accounting related to affiliate Samsung Bioepis, but the company says its accounting meets IFRS standards and denies any transgressions. Samsung BioLogics could face a penalty, depending on the outcome of upcoming financial authority meetings and whether Biogen exercises its call option on Samsung Bioepis in the coming months.
Samsung BioLogics Under Spotlight Over Accounting Handling Of Biogen JV
Samsung BioLogics shares plunge on suspicions it has violated accounting related to affiliate Samsung Bioepis, but the company says its accounting meets IFRS standards and denies any transgressions. Samsung BioLogics could face a penalty, depending on the outcome of upcoming financial authority meetings and whether Biogen exercises its call option on Samsung Bioepis in the coming months.
Korea Govt Partners With J&J To Bring In Local JLABS Site
In collaboration with the national health ministry, J&J’s JLAB program is coming to South Korea as its third destination in Asia, underscoring the country’s increasing need to access multinationals’ know-how and its growing impact on the global biotech landscape and innovation.